Your session is about to expire
← Back to Search
Caspase Inhibitor
Emricasan (5 mg) for Cirrhosis (ENCORE-LF Trial)
Phase 2
Waitlist Available
Research Sponsored by Conatus Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline - final treatment visit (at least 48 weeks to a max of 120 weeks)
Awards & highlights
Summary
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.
Eligible Conditions
- Cirrhosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline - final treatment visit (at least 48 weeks to a max of 120 weeks)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline - final treatment visit (at least 48 weeks to a max of 120 weeks)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Decrease in all-cause and liver specific mortality
Decrease in liver transplantation rates
Decrease in new decompensation events
+3 moreTrial Design
3Treatment groups
Active Control
Placebo Group
Group I: Emricasan (5 mg)Active Control1 Intervention
Emricasan 5mg
Group II: Emricasan (25 mg)Active Control1 Intervention
Emricasan 25 mg
Group III: PlaceboPlacebo Group1 Intervention
Matching placebo
Find a Location
Who is running the clinical trial?
Conatus Pharmaceuticals Inc.Lead Sponsor
18 Previous Clinical Trials
1,567 Total Patients Enrolled
Jean L Chan, MDStudy DirectorConatus Pharmaceuticals
1 Previous Clinical Trials
318 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger